Bio-Techne Sale to Merck KGaA at $73 Cash Per Share Under Scrutiny
TECH•TECH•TECH•TECH•Halper Sadeh LLC has opened an investigation into Bio-Techne’s proposed sale to Merck KGaA for $73 per share in cash for potential breaches of fiduciary duties and federal securities laws. The firm warns that the transaction agreement may limit superior competing offers and encourages shareholders to explore their legal rights.
Halper Sadeh LLC has initiated a formal inquiry into the Bio-Techne transaction with Merck KGaA, citing potential violations of federal securities laws and breaches of fiduciary duty. Shareholders are informed that the firm will handle matters on a contingent fee basis, with no upfront legal costs required.
Under the deal, Merck KGaA will acquire Bio-Techne for $73 in cash per share, and the agreement may include provisions restricting higher bids. The investigation could prompt demands for increased consideration, additional disclosures or other shareholder protections before the merger is finalized.
